Vedolizumab and Anti-Tumour Necrosis Factor alpha Real-World Outcomes in Biologic-Naive Inflammatory Bowel Disease Patients: Results from the EVOLVE Study Article

Industry Collaboration International Collaboration

cited authors

  • Bressler, Brian; Yarur, Andres; Silverberg, Mark S.; Bassel, Marielle; Bellaguarda, Emanuelle; Fourment, Chris; Gatopoulou, Anthie; Karatzas, Pantelis; Kopylov, Uri; Michalopoulos, George; Michopoulos, Spyridon; Navaneethan, Udayakumar; Rubin, David T.; Siffledeen, Jesse; Singh, Andrew; Soufleris, Konstantinos; Stein, Dara; Demuth, Dirk; Mantzaris, Gerassimos J.

Publication Date

  • October 1, 2021

webpage

published in

category

keywords

  • Vedolizumab
  • biologic-naive
  • real-world effectiveness

start page

  • 1694

end page

  • 1706

volume

  • 15

issue

  • 10